Compare MGM Resorts International (MGM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs State Street SPDR S&P Biotech ETF — how do they compare? MGM Resorts International trades at $40.18 (market cap $10.25B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: MGM Resorts International pays a 0.03% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, MGM Resorts International nearer its low. Which is the better fit depends on your goals.
| MGM | XBI | |
|---|---|---|
Market Cap | $10.25B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $50.69 | $169.55 |
52-Week Low | $30.72 | $93.43 |
Enterprise Value | $37.55B | — |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International trades at $40.74, down 1.16% on the day, as the stock faces technical bearish pressure despite strong analyst support. The company reported mixed quarterly earnings with two beats and one miss in recent quarters, while maintaining stable revenue around $17.5 billion. Recent news highlights include BetMGM's football season enhancements and ongoing investigation into Barry Diller's $48.30 per share acquisition offer.
MGM presents a compelling valuation case with a P/S ratio of 0.61 below industry averages, supported by 51% analyst buy ratings and a $51.61 consensus price target offering 27% upside. However, declining profit margins and negative cash flow trends pose fundamental concerns, while the bearish technical outlook suggests near-term pressure. The acquisition investigation adds regulatory uncertainty to the investment thesis.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
